MOB3B

Summary

MOB3B (MOB kinase activator 3B, HGNC:23825) is a protein-coding gene on chromosome 9p21.2, encoding MOB kinase activator 3B (Q86TA1). Modulates LATS1 expression in the Hippo signaling pathway which plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis.

The protein encoded by this gene shares similarity with the yeast Mob1 protein. Yeast Mob1 binds Mps1p, a protein kinase essential for spindle pole body duplication and mitotic checkpoint regulation. This gene is located on the opposite strand as the interferon kappa precursor (IFNK) gene.

Source: NCBI Gene 79817 — RefSeq curated summary.

At a glance

• GWAS associations: 11
• Clinical variants (ClinVar): 34 total
• MANE Select transcript: NM_024761

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23825
Approved symbol	MOB3B
Name	MOB kinase activator 3B
Location	9p21.2
Locus type	gene with protein product
Status	Approved
Aliases	MOB1D, FLJ13204
Ensembl gene	ENSG00000120162
Ensembl biotype	protein_coding
OMIM	617652
Entrez	79817

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 9 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000262244, ENST00000603061, ENST00000900189, ENST00000900190, ENST00000900191, ENST00000900192, ENST00000900193, ENST00000900194, ENST00000967821, ENST00000967822

RefSeq mRNA: 1 — MANE Select: NM_024761 NM_024761

CCDS: CCDS6520

Canonical transcript exons

ENST00000262244 — 4 exons

Exon	Start	End
ENSE00001017125	27359034	27359236
ENSE00001146607	27455133	27455748
ENSE00001252402	27325209	27330616
ENSE00001527984	27529555	27529814

Expression profiles

Bgee: expression breadth ubiquitous, 260 present calls, max score 94.49.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.9210 / max 158.0828, expressed in 1049 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
100343	6.1318	1031
100342	0.3103	142
100335	0.1495	36
100334	0.1228	33
100340	0.1213	48
100341	0.0853	33

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
inferior vagus X ganglion	UBERON:0005363	94.49	gold quality
ventricular zone	UBERON:0003053	93.65	gold quality
lateral globus pallidus	UBERON:0002476	93.42	gold quality
jejunal mucosa	UBERON:0000399	93.40	gold quality
secondary oocyte	CL:0000655	93.01	gold quality
subthalamic nucleus	UBERON:0001906	92.57	gold quality
globus pallidus	UBERON:0001875	92.24	gold quality
oocyte	CL:0000023	91.85	gold quality
ileal mucosa	UBERON:0000331	91.68	silver quality
medial globus pallidus	UBERON:0002477	91.68	gold quality
dorsal plus ventral thalamus	UBERON:0001897	91.15	gold quality
spinal cord	UBERON:0002240	90.65	gold quality
colonic mucosa	UBERON:0000317	90.56	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	90.33	gold quality
mucosa of sigmoid colon	UBERON:0004993	90.25	gold quality
substantia nigra pars reticulata	UBERON:0001966	89.79	gold quality
lateral nuclear group of thalamus	UBERON:0002736	89.29	gold quality
ventral tegmental area	UBERON:0002691	88.98	gold quality
endothelial cell	CL:0000115	88.94	gold quality
skin of hip	UBERON:0001554	88.65	gold quality
corpus callosum	UBERON:0002336	88.37	gold quality
pons	UBERON:0000988	88.21	gold quality
superior vestibular nucleus	UBERON:0007227	88.07	gold quality
duodenum	UBERON:0002114	88.02	gold quality
medulla oblongata	UBERON:0001896	87.60	gold quality
upper leg skin	UBERON:0004262	87.59	gold quality
ganglionic eminence	UBERON:0004023	87.24	gold quality
decidua	UBERON:0002450	86.40	gold quality
adult organism	UBERON:0007023	85.91	gold quality
left ovary	UBERON:0002119	85.86	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.71
E-GEOD-36552	no	294.46

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

245 targeting MOB3B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-3134	100.00	66.43	777
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-4745-5P	99.98	65.95	1028
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-6508-5P	99.92	70.67	2465

Literature-anchored findings (GeneRIF, showing 1)

• low levels of hMOB3B are closely associated with aggressive clinicopathologic features in patients with prostate cancer. The results suggest that hMOB3B may act as a tumor suppressor in human prostate cancer. (PMID:26130958)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
mus_musculus	Mob3b	ENSMUSG00000073910
rattus_norvegicus	Mob3b	ENSRNOG00000009453
drosophila_melanogaster	Mob3	FBGN0259482
caenorhabditis_elegans		WBGENE00020447

Paralogs (6): MOB1A (ENSG00000114978), MOB4 (ENSG00000115540), MOB3C (ENSG00000142961), MOB3A (ENSG00000172081), MOB1B (ENSG00000173542), MOB2 (ENSG00000182208)

Protein

Protein identifiers

MOB kinase activator 3B — Q86TA1 (reviewed: Q86TA1)

Alternative names: Mob1 homolog 2b, Mps one binder kinase activator-like 2B

All UniProt accessions (1): Q86TA1

UniProt curated annotations — full annotation on UniProt →

Function. Modulates LATS1 expression in the Hippo signaling pathway which plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis.

Induction. Expression at transcriptional level is activated by the expression of the neighboring long non-coding RNA (lncRNA) EMICERI.

Similarity. Belongs to the MOB1/phocein family.

RefSeq proteins (1): NP_079037* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005301	MOB_kinase_act_fam	Family
IPR036703	MOB_kinase_act_sf	Homologous_superfamily

Pfam: PF03637

UniProt features (7 total): binding site 4, sequence conflict 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q86TA1-F1	90.13	0.74

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (4): 82; 87; 164; 169

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 183 (showing top): TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, XU_GH1_AUTOCRINE_TARGETS_UP, TGCACTT_MIR519C_MIR519B_MIR519A, LINDGREN_BLADDER_CANCER_CLUSTER_3_DN, GTTAAAG_MIR302B, GOBP_HIPPO_SIGNALING, GOMF_KINASE_ACTIVATOR_ACTIVITY, FOSTER_TOLERANT_MACROPHAGE_UP, TCCAGAG_MIR518C, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN, SENESE_HDAC3_TARGETS_DN, GOMF_ENZYME_ACTIVATOR_ACTIVITY, GOMF_ENZYME_REGULATOR_ACTIVITY, CAGTGTT_MIR141_MIR200A, MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME3

GO Biological Process (2): signal transduction (GO:0007165), regulation of hippo signaling (GO:0035330)

GO Molecular Function (3): protein kinase activator activity (GO:0030295), metal ion binding (GO:0046872), protein binding (GO:0005515)

GO Cellular Component (2): nucleus (GO:0005634), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
hippo signaling	1
regulation of intracellular signal transduction	1
protein kinase activity	1
kinase activator activity	1
protein kinase regulator activity	1
cation binding	1
binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

324 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MOB3B	IFNK	Q9P0W0	647
MOB3B	LINGO2	Q7L985	607
MOB3B	EQTN	Q9NQ60	542
MOB3B	C9orf72	Q96LT7	536
MOB3B	CNKSR2	Q8WXI2	505
MOB3B	LRRC19	Q9H756	505
MOB3B	FBXO30	Q8TB52	473
MOB3B	STK38	Q15208	451
MOB3B	CCDC181	Q5TID7	447
MOB3B	MAPK14	Q16539	444
MOB3B	CHMP2B	Q9UQN3	443
MOB3B	STK38L	Q9Y2H1	400
MOB3B	WDR41	Q9HAD4	398
MOB3B	SMCR8	Q8TEV9	395
MOB3B	ZNF280A	P59817	378

IntAct

10 interactions, top by confidence:

A	B	Type	Score
NT5C2	MOB3B	psi-mi:“MI:0915”(physical association)	0.620
STK3	MOB3B	psi-mi:“MI:0915”(physical association)	0.560
PPBP	MOB3B	psi-mi:“MI:0915”(physical association)	0.370
CNKSR2	MOB3B	psi-mi:“MI:0915”(physical association)	0.000
MOB3B	MAPK14	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (34): MOB3B (Two-hybrid), MOB3B (Affinity Capture-MS), MOB3B (Two-hybrid), MOB3B (Affinity Capture-RNA), DOCK7 (Proximity Label-MS), MAP4K4 (Proximity Label-MS), MINK1 (Proximity Label-MS), DOCK9 (Proximity Label-MS), RPP14 (Proximity Label-MS), KRI1 (Proximity Label-MS), HSPB1 (Proximity Label-MS), HAX1 (Proximity Label-MS), SFXN4 (Proximity Label-MS), PRPS1 (Proximity Label-MS), MAP2K1 (Proximity Label-MS)

ESM2 similar proteins: A0A223HDI2, A2BG43, B0BLT4, B0BNM9, B0YN54, O64587, O74432, P68265, P68266, P97371, P97372, Q06323, Q0VCQ0, Q19555, Q29RK9, Q4U5R3, Q54QV0, Q58D63, Q5E9G3, Q5F495, Q5HZ92, Q5R5Z0, Q5RDB1, Q5TA50, Q5XIS2, Q63797, Q63798, Q63ZQ3, Q64L94, Q66JG2, Q6DBQ8, Q6NLQ3, Q6NU44, Q6PEB6, Q7K0E3, Q7XVN7, Q863Z0, Q86TA1, Q8BS40, Q8L7U7

Diamond homologs: F4K494, F4K495, O74558, O94360, P40484, P43563, Q29RK9, Q2LZ59, Q2WBN3, Q3T1J9, Q54BM4, Q54CR8, Q54QV0, Q54XJ0, Q58D63, Q5ABC6, Q5EAA4, Q5R5Z0, Q5RAE0, Q70IA6, Q70IA8, Q7L9L4, Q86TA1, Q8BJG4, Q8BPB0, Q8BSU7, Q8GYX0, Q8IQG1, Q8VE04, Q8VI63, Q921Y0, Q949G5, Q95RA8, Q96BX8, Q9FHI1, Q9H8S9, Q9P601, Q9VL13

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

34 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	18
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2205 predictions. Top by Δscore:

Variant	Effect	Δscore
9:27359029:CTTA:C	donor_loss	1.0000
9:27359030:TTA:T	donor_loss	1.0000
9:27359032:A:AC	donor_gain	1.0000
9:27359033:C:CC	donor_gain	1.0000
9:27359033:CCA:C	donor_gain	1.0000
9:27359033:CCAA:C	donor_gain	1.0000
9:27359033:CCAAA:C	donor_gain	1.0000
9:27359232:AACAC:A	acceptor_gain	1.0000
9:27359233:ACAC:A	acceptor_gain	1.0000
9:27359233:ACACC:A	acceptor_gain	1.0000
9:27359234:CAC:C	acceptor_gain	1.0000
9:27359234:CACC:C	acceptor_gain	1.0000
9:27359234:CACCT:C	acceptor_gain	1.0000
9:27359235:AC:A	acceptor_gain	1.0000
9:27359235:ACC:A	acceptor_gain	1.0000
9:27359236:CC:C	acceptor_gain	1.0000
9:27359236:CCT:C	acceptor_gain	1.0000
9:27359237:C:A	acceptor_gain	1.0000
9:27359237:C:CC	acceptor_gain	1.0000
9:27455131:AC:A	donor_gain	1.0000
9:27455132:CC:C	donor_gain	1.0000
9:27455132:CCCA:C	donor_gain	1.0000
9:27489985:A:C	donor_gain	1.0000
9:27359032:AC:A	donor_gain	0.9900
9:27359033:CC:C	donor_gain	0.9900
9:27359238:T:G	acceptor_gain	0.9900
9:27368413:T:TA	donor_gain	0.9900
9:27398172:CAT:C	acceptor_gain	0.9900
9:27398174:T:TC	acceptor_gain	0.9900
9:27455126:AACTT:A	donor_loss	0.9900

AlphaMissense

1452 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:27455189:A:G	L121P	1.000
9:27455210:G:T	A114D	1.000
9:27455251:C:A	W100C	1.000
9:27455251:C:G	W100C	1.000
9:27455252:C:G	W100S	1.000
9:27455253:A:G	W100R	1.000
9:27455253:A:T	W100R	1.000
9:27455259:A:G	Y98H	1.000
9:27455276:C:T	G92E	1.000
9:27455292:A:G	C87R	1.000
9:27455305:G:C	C82W	1.000
9:27455333:A:G	L73P	1.000
9:27359094:T:A	K187N	0.999
9:27359094:T:G	K187N	0.999
9:27359099:A:C	Y186D	0.999
9:27359102:A:G	C185R	0.999
9:27359110:A:T	V182D	0.999
9:27359163:G:C	H164Q	0.999
9:27359163:G:T	H164Q	0.999
9:27359165:G:C	H164D	0.999
9:27359167:A:T	V163D	0.999
9:27359176:C:G	R160P	0.999
9:27359177:G:C	R160G	0.999
9:27359182:A:G	L158P	0.999
9:27359185:C:G	R157P	0.999
9:27359186:G:T	R157S	0.999
9:27359226:G:C	F143L	0.999
9:27359226:G:T	F143L	0.999
9:27359228:A:G	F143L	0.999
9:27455147:A:G	F135S	0.999

dbSNP variants (sampled 300 via entrez): RS1000014305 (9:27473564 G>A), RS1000015435 (9:27369123 C>A,T), RS1000034664 (9:27474269 C>G), RS1000059670 (9:27424700 T>C,G), RS1000073314 (9:27332751 C>T), RS1000090202 (9:27468194 T>C), RS1000093339 (9:27328591 G>A), RS1000113692 (9:27431192 C>T), RS1000123814 (9:27428849 T>C), RS1000128546 (9:27508580 A>G), RS1000142759 (9:27470059 T>C), RS1000160045 (9:27440208 G>A), RS1000166392 (9:27363372 C>T), RS1000167056 (9:27328942 T>C), RS1000167576 (9:27457756 G>T)

Disease associations

OMIM: gene MIM:617652 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

11 associations (top):

Study	Trait	p-value
GCST000481_2	Amyotrophic lateral sclerosis	1.000000e-08
GCST000481_7	Amyotrophic lateral sclerosis	7.000000e-09
GCST000675_8	Heart failure	5.000000e-06
GCST000781_1	Amyotrophic lateral sclerosis	9.000000e-11
GCST001847_1	Urinary symptoms in response to radiotherapy in prostate cancer	7.000000e-07
GCST003831_45	Asthma	7.000000e-10
GCST003831_47	Asthma	2.000000e-08
GCST003833_23	Adult asthma	3.000000e-07
GCST003833_24	Adult asthma	2.000000e-06
GCST004484_7	Plasma trimethylamine N-oxide levels	3.000000e-07
GCST005851_12	Delirium	9.000000e-07

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0008008	lower urinary tract symptom
EFO:0005691	plasma trimethylamine N-oxide measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

3 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs2814707	Efficacy	3	Tumor necrosis factor alpha (TNF-alpha) inhibitors	Rheumatoid arthritis
rs7046653	Efficacy	3	Tumor necrosis factor alpha (TNF-alpha) inhibitors	Rheumatoid arthritis
rs868856	Efficacy	3	Tumor necrosis factor alpha (TNF-alpha) inhibitors	Rheumatoid arthritis

PharmGKB variants

3 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs868856	MOB3B	3	2.25	1	Tumor necrosis factor alpha (TNF-alpha) inhibitors
rs2814707	MOB3B	3	2.25	1	Tumor necrosis factor alpha (TNF-alpha) inhibitors
rs7046653	MOB3B	3	2.25	1	Tumor necrosis factor alpha (TNF-alpha) inhibitors

CTD chemical–gene interactions

46 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, decreases methylation, increases expression	5
trichostatin A	affects cotreatment, decreases expression	3
Benzo(a)pyrene	affects methylation, decreases expression, increases expression	3
sodium arsenite	decreases expression, increases expression	2
entinostat	decreases expression, affects cotreatment	2
Cyclosporine	decreases expression, increases expression	2
aristolochic acid I	decreases expression	1
methylmercuric chloride	decreases expression	1
propionaldehyde	increases expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
bisphenol A	increases expression, affects cotreatment	1
arsenite	increases methylation	1
sulforaphane	decreases expression	1
butyraldehyde	increases expression	1
potassium chromate(VI)	increases expression	1
cupric oxide	decreases expression	1
hydroquinone	decreases expression	1
pentanal	increases expression	1
perfluorooctane sulfonic acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	decreases expression	1
dorsomorphin	decreases expression, affects cotreatment	1
jinfukang	affects cotreatment, decreases expression	1
NSC 689534	decreases expression, affects binding	1
Air Pollutants	increases abundance, decreases expression	1
Aldehydes	increases expression	1
Cisplatin	affects cotreatment, decreases expression	1
Copper	affects binding, decreases expression	1
Dexamethasone	increases expression, affects cotreatment	1
Diazinon	increases methylation	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.